Kamada Ltd. (KMDA)
USD 5.76
(-1.37%)
USD 5.76
(-1.37%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 8.28 Million USD | 456.92% |
| 2022 | -2.32 Million USD | -4.08% |
| 2021 | -2.23 Million USD | -113.01% |
| 2020 | 17.14 Million USD | -22.97% |
| 2019 | 22.25 Million USD | -0.2% |
| 2018 | 22.29 Million USD | 223.08% |
| 2017 | 6.9 Million USD | 202.5% |
| 2016 | -6.73 Million USD | 40.26% |
| 2015 | -11.27 Million USD | 10.81% |
| 2014 | -12.63 Million USD | -2952.37% |
| 2013 | 443 Thousand USD | 70.38% |
| 2012 | 260 Thousand USD | 107.44% |
| 2011 | -3.49 Million USD | 76.98% |
| 2010 | -15.17 Million USD | 31.14% |
| 2009 | -22.03 Million USD | -77.03% |
| 2008 | -12.44 Million USD | 45.64% |
| 2007 | -22.89 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 4.42 Million USD | 87.15% |
| 2024 Q1 | 2.36 Million USD | -53.24% |
| 2023 Q4 | 5.05 Million USD | 56.93% |
| 2023 FY | 8.28 Million USD | 456.92% |
| 2023 Q2 | 1.81 Million USD | 200.17% |
| 2023 Q3 | 3.22 Million USD | 77.87% |
| 2023 Q1 | -1.8 Million USD | -161.45% |
| 2022 Q4 | 2.94 Million USD | 508.26% |
| 2022 Q3 | 484 Thousand USD | 112.34% |
| 2022 FY | -2.32 Million USD | -4.08% |
| 2022 Q1 | -1.82 Million USD | 63.51% |
| 2022 Q2 | -3.92 Million USD | -114.5% |
| 2021 Q4 | -5 Million USD | -492.78% |
| 2021 Q2 | 937 Thousand USD | -65.13% |
| 2021 Q3 | -845 Thousand USD | -190.18% |
| 2021 FY | -2.23 Million USD | -113.01% |
| 2021 Q1 | 2.68 Million USD | 64.95% |
| 2020 Q4 | 1.62 Million USD | -76.17% |
| 2020 Q2 | 3.45 Million USD | -33.73% |
| 2020 Q1 | 5.21 Million USD | -2.69% |
| 2020 Q3 | 6.83 Million USD | 97.66% |
| 2020 FY | 17.14 Million USD | -22.97% |
| 2019 FY | 22.25 Million USD | -0.2% |
| 2019 Q3 | 5.82 Million USD | -5.21% |
| 2019 Q4 | 5.36 Million USD | -7.92% |
| 2019 Q2 | 6.14 Million USD | 24.78% |
| 2019 Q1 | 4.92 Million USD | -72.26% |
| 2018 Q1 | 1.25 Million USD | -79.91% |
| 2018 Q4 | 17.74 Million USD | 842.16% |
| 2018 Q3 | -2.39 Million USD | -142.05% |
| 2018 FY | 22.29 Million USD | 223.08% |
| 2018 Q2 | 5.68 Million USD | 352.71% |
| 2017 Q3 | -236 Thousand USD | -104.85% |
| 2017 FY | 6.9 Million USD | 202.5% |
| 2017 Q4 | 6.25 Million USD | 2749.15% |
| 2017 Q2 | 4.86 Million USD | 222.25% |
| 2017 Q1 | -3.97 Million USD | -119.97% |
| 2016 FY | -6.73 Million USD | 40.26% |
| 2016 Q1 | -2.29 Million USD | -332.69% |
| 2016 Q2 | -1.58 Million USD | 31.06% |
| 2016 Q3 | -1.04 Million USD | 34.32% |
| 2016 Q4 | -1.8 Million USD | -73.68% |
| 2015 Q2 | -2.34 Million USD | 55.76% |
| 2015 Q4 | 988 Thousand USD | 121.38% |
| 2015 Q3 | -4.62 Million USD | -97.35% |
| 2015 Q1 | -5.29 Million USD | -403.38% |
| 2015 FY | -11.27 Million USD | 10.81% |
| 2014 Q3 | -2.89 Million USD | 65.36% |
| 2014 Q1 | -3.12 Million USD | -301.29% |
| 2014 FY | -12.63 Million USD | -2952.37% |
| 2014 Q2 | -8.36 Million USD | -167.84% |
| 2014 Q4 | 1.74 Million USD | 160.23% |
| 2013 Q3 | 37 Thousand USD | -95.84% |
| 2013 Q2 | 890 Thousand USD | 143.73% |
| 2013 FY | 443 Thousand USD | 70.38% |
| 2013 Q4 | 1.55 Million USD | 4091.89% |
| 2013 Q1 | -2.03 Million USD | -171.2% |
| 2012 Q4 | 2.85 Million USD | 2674.76% |
| 2012 FY | 260 Thousand USD | 107.44% |
| 2012 Q2 | -2.22 Million USD | 0.0% |
| 2012 Q3 | 103 Thousand USD | 104.62% |
| 2011 FY | -3.49 Million USD | 76.98% |
| 2010 FY | -15.17 Million USD | 31.14% |
| 2009 FY | -22.03 Million USD | -77.03% |
| 2008 FY | -12.44 Million USD | 45.64% |
| 2007 FY | -22.89 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Journey Medical Corporation | -3.85 Million USD | 315.001% |
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | 55.887% |
| Aquestive Therapeutics, Inc. | -7.87 Million USD | 205.26% |
| Pacira BioSciences, Inc. | 41.95 Million USD | 80.255% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | 283.842% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | 283.842% |
| SCYNEXIS, Inc. | 67.04 Million USD | 87.643% |
| Safety Shot Inc | -15.08 Million USD | 154.923% |
| Alpha Teknova, Inc. | -36.78 Million USD | 122.523% |
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | 82.797% |
| Bright Green Corporation | -13.12 Million USD | 163.103% |
| Dynavax Technologies Corporation | -6.38 Million USD | 229.66% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 103.959% |
| Cosmos Health Inc. | -18.54 Million USD | 144.675% |
| PainReform Ltd. | -9.34 Million USD | 188.656% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | 367.352% |
| Embecta Corp. | 70.4 Million USD | 88.233% |
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | 105.931% |
| Procaps Group, S.A. | 42.54 Million USD | 80.527% |
| Theratechnologies Inc. | -23.95 Million USD | 134.579% |
| Harrow Health, Inc. | -24.41 Million USD | 133.936% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | 271.334% |
| Biofrontera Inc. | -20.13 Million USD | 141.15% |
| DURECT Corporation | -27.62 Million USD | 129.988% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | -529.483% |
| Cronos Group Inc. | -73.96 Million USD | 111.2% |
| OptiNose, Inc. | -35.48 Million USD | 123.346% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 100.827% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 119.631% |
| RedHill Biopharma Ltd. | 23.91 Million USD | 65.362% |
| Organogenesis Holdings Inc. | 4.94 Million USD | -67.523% |
| Guardion Health Sciences, Inc. | 158.03 Thousand USD | -5141.943% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | 231.925% |
| Radius Health, Inc. | -25.79 Million USD | 132.12% |
| Universe Pharmaceuticals INC | -6.16 Million USD | 234.414% |
| ProPhase Labs, Inc. | -16.78 Million USD | 149.362% |
| Phibro Animal Health Corporation | 2.41 Million USD | -242.881% |
| Procaps Group S.A. | 42.54 Million USD | 80.527% |
| Alvotech | -551.73 Million USD | 101.501% |
| TherapeuticsMD, Inc. | -10.27 Million USD | 180.599% |
| Viatris Inc. | 54.7 Million USD | 84.856% |
| Rockwell Medical, Inc. | -8.43 Million USD | 198.163% |
| Aytu BioPharma, Inc. | -15.84 Million USD | 152.285% |
| SIGA Technologies, Inc. | 68.06 Million USD | 87.83% |
| Tilray Brands, Inc. | -244.98 Million USD | 103.381% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | 31.041% |
| Shineco, Inc. | -22.44 Million USD | 136.901% |
| PetIQ, Inc. | 2.13 Million USD | -288.738% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | 292.569% |
| Incannex Healthcare Limited | -18.45 Million USD | 144.878% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 96.682% |
| Alimera Sciences, Inc. | -20.13 Million USD | 141.148% |
| Silver Spike Investment Corp. | 7.34 Million USD | -12.859% |
| Assertio Holdings, Inc. | -331.94 Million USD | 102.496% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | 225.654% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | 201.48% |
| Clever Leaves Holdings Inc. | -17.89 Million USD | 146.282% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 141.302% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | 105.169% |
| Hempacco Co., Inc. | -13.12 Million USD | 163.111% |
| Talphera, Inc. | -18.39 Million USD | 145.029% |
| Alvotech | -551.73 Million USD | 101.501% |
| Eagle Pharmaceuticals, Inc. | 35.64 Million USD | 76.758% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 97.464% |
| Currenc Group, Inc. | -15.3 Million USD | 154.121% |
| Indivior PLC | 2 Million USD | -314.2% |
| Evoke Pharma, Inc. | -7.79 Million USD | 206.31% |
| Flora Growth Corp. | -57.03 Million USD | 114.524% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 141.302% |
| Evolus, Inc. | -61.68 Million USD | 113.43% |
| HUTCHMED (China) Limited | 100.78 Million USD | 91.78% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 93.977% |
| Akanda Corp. | -32.27 Million USD | 125.667% |